TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer.
Zhang HL, Hu BX, Ye ZP, Li ZL, Liu S, Zhong WQ, Du T, Yang D, Mai J, Li LC, Chen YH, Zhu XY, Li X, Feng GK, Zhu XF, Deng R.
Zhang HL, et al. Among authors: li zl, li x, li lc.
Sci Transl Med. 2024 Jun 26;16(753):eadk0330. doi: 10.1126/scitranslmed.adk0330. Epub 2024 Jun 26.
Sci Transl Med. 2024.
PMID: 38924427